Reversal by andexanet alfa on endothelial suppression of platelet activation. Samples of PRP were incubated with andexanet alfa (150 nM) and/or anti-TFPI mAb (250 nM). Triggering in control wells (A,B) or endothelial-covered wells (C,D) was with 1 pM TF. Measured was platelet ATP secretion by luciferin-luciferase interaction. Shown are representative luminescence curves (A,C) and calculated lag times to onset (B,D). Means ± SD (n = 3). ∗P < .05, ∗∗P < .01 (ANOVA).
Figure 7.

Reversal by andexanet alfa on endothelial suppression of platelet activation. Samples of PRP were incubated with andexanet alfa (150 nM) and/or anti-TFPI mAb (250 nM). Triggering in control wells (A,B) or endothelial-covered wells (C,D) was with 1 pM TF. Measured was platelet ATP secretion by luciferin-luciferase interaction. Shown are representative luminescence curves (A,C) and calculated lag times to onset (B,D). Means ± SD (n = 3). ∗P < .05, ∗∗P < .01 (ANOVA).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal